Several small-molecule kinase inhibitors that target components of the MAPK signaling cascade have been approved by the US Food and Drug Administration for the treatment of BRAF-mutant melanoma, including trametinib, dabrafenib, and vemurafenib, or the treatment of kidney and liver cancers with sorafenib1. This evidence concerns the gene BRAF and melanoma.